PMID- 27760978
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20190606
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 22
DP  - 2016 Oct 20
TI  - Efficacy and Safety of Danshen Compound Tablets in Preventing 
      Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A 
      Multicenter Retrospective Study.
PG  - 3835-3842
AB  - BACKGROUND Currently available antithrombotic prophylaxis is not perfectly 
      reliable in elderly patients. The aim of this retrospective study was to evaluate 
      the efficacy and safety of Compound Danshen Tablet (CDT) in preventing 
      thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based 
      regimens. MATERIAL AND METHODS MM patients treated with thalidomide-based 
      regimens were retrospectively reviewed between January 2008 and March 2015. 
      Patients were categorized into 3 cohorts based on thromboembolic prophylaxis 
      used: CDT, Warfarin Tablet, and no prophylaxis. Venous thromboembolism (VTE), 
      other adverse effects (AEs), and the changes of D-dimer and fibrinogen levels 
      were monitored. RESULTS Seven out of 313 MM patients (2.24%) developed venous 
      thrombosis events (VTE) in this retrospective study, all clustering in the no 
      prophylaxis cohort. Three patients of the Warfarin cohort (3.19%) experienced 
      hemorrhage. Neither VTE events nor serious AEs were observed in the CDT cohort. 
      Following Compound Danshen or Warfarin treatment for 3 months, the D-dimer and 
      fibrinogen levels (in particular the D-dimer level) (all P<0.05), were obviously 
      decreased relative to their respective baselines and the no prophylaxis cohort. 
      In contrast, the 2 blotting parameters were significantly increased in the no 
      prophylaxis cohort relative to the baseline level (All P<0.05), and were even 
      higher in the patients experiencing VTE compared to the no VTE patients (P<0.0001 
      and P=0.016, respectively). CONCLUSIONS Our findings indicate CDT is an effective 
      therapy for preventing VTE in MM patients treated with thalidomide-based 
      regimens, and is well tolerated in long-term use.
FAU - Yin, Qing-Song
AU  - Yin QS
AD  - Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan 
      Cancer Hospital, Zhengzhou, Henan, China (mainland).
FAU - Chen, Lin
AU  - Chen L
AD  - Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan 
      Cancer Hospital, Zhengzhou, Henan, China (mainland).
FAU - Mi, Rui-Hua
AU  - Mi RH
AD  - Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan 
      Cancer Hospital, Zhengzhou, Henan, China (mainland).
FAU - Ai, Hao
AU  - Ai H
AD  - Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan 
      Cancer Hospital, Zhengzhou, Henan, China (mainland).
FAU - Yin, Jun-Jie
AU  - Yin JJ
AD  - Department of Leukemia, The Central Hospital of Xinxiang, Xinxiang, Henan, China 
      (mainland).
FAU - Liu, Xiao-Juan
AU  - Liu XJ
AD  - Department of Leukemia , The Second People's Hospital of Jiaozuo, Jiaozuo, Henan, 
      China (mainland).
FAU - Wei, Xu-Dong
AU  - Wei XD
AD  - Department of Leukemia , Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20161020
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Plant Preparations)
RN  - 0 (Tablets)
RN  - 0 (fibrin fragment D)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 5Q7ZVV76EI (Warfarin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*blood/*drug therapy
MH  - Phytotherapy
MH  - Plant Preparations/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Salvia miltiorrhiza
MH  - Tablets
MH  - Thalidomide/adverse effects
MH  - Venous Thromboembolism/blood/chemically induced/*prevention & control
MH  - Warfarin/administration & dosage
PMC - PMC5077292
EDAT- 2016/10/21 06:00
MHDA- 2017/05/04 06:00
PMCR- 2016/10/20
CRDT- 2016/10/21 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
PHST- 2016/10/20 00:00 [pmc-release]
AID - 900575 [pii]
AID - 10.12659/msm.900575 [doi]
PST - epublish
SO  - Med Sci Monit. 2016 Oct 20;22:3835-3842. doi: 10.12659/msm.900575.